Get the Stockscreener App
94.62
4.51%
4.08
After Hours:
96.29
1.67
+1.76%
Globus Medical Inc stock is traded at $94.62, with a volume of 4.67M.
It is up +4.51% in the last 24 hours and up +6.31% over the past month.
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
See More
Previous Close:
$90.54
Open:
$100.1
24h Volume:
4.67M
Relative Volume:
2.75
Market Cap:
$12.66B
Revenue:
$2.51B
Net Income/Loss:
$185.56M
P/E Ratio:
70.61
EPS:
1.34
Net Cash Flow:
$517.59M
1W Performance:
+8.37%
1M Performance:
+6.31%
6M Performance:
+67.17%
1Y Performance:
+9.32%
1-Day Range:
$94.02
$101.40
1-Week Range:
$85.65
$101.40
52-Week Range:
$51.79
$101.40
Globus Medical Inc Stock (GMED) Company Profile
Name
Globus Medical Inc
Sector
Industry
Phone
610-930-1800
Address
2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA
Compare GMED with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GMED
Globus Medical Inc
|
94.62 | 12.12B | 2.51B | 185.56M | 517.59M | 1.34 |
|
ABT
Abbott Laboratories
|
126.18 | 220.91B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.38 | 146.24B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
367.21 | 140.64B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
98.69 | 127.91B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.58 | 49.23B | 5.88B | 1.34B | 799.60M | 2.3489 |
Globus Medical Inc Stock (GMED) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-25 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-07-25 | Upgrade | Truist | Hold → Buy |
| Oct-28-25 | Resumed | Stifel | Hold |
| May-27-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-10-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Dec-02-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-20-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-18-24 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-20-23 | Initiated | ROTH MKM | Buy |
| Sep-19-23 | Upgrade | Stifel | Hold → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-13-23 | Downgrade | BofA Securities | Buy → Underperform |
| Feb-10-23 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-10-23 | Downgrade | Loop Capital | Buy → Hold |
| Feb-10-23 | Downgrade | Needham | Buy → Hold |
| Feb-10-23 | Downgrade | Truist | Buy → Hold |
| Feb-10-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-28-22 | Initiated | Wells Fargo | Overweight |
| Jan-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-13-21 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-29-21 | Initiated | Loop Capital | Buy |
| Feb-18-21 | Resumed | Needham | Buy |
| Dec-08-20 | Initiated | Citigroup | Buy |
| Oct-20-20 | Initiated | Stifel | Hold |
| Aug-06-20 | Reiterated | Needham | Buy |
| Aug-06-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-21-20 | Initiated | Northland Capital | Market Perform |
| Jul-06-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-08-20 | Reiterated | Needham | Buy |
| Mar-18-20 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Dec-12-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Aug-02-19 | Reiterated | Needham | Buy |
| May-24-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
| May-03-19 | Reiterated | Needham | Buy |
| Feb-28-19 | Upgrade | UBS | Neutral → Buy |
| Jan-02-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-02-18 | Reiterated | Needham | Buy |
| Jun-27-18 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jun-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| May-03-18 | Reiterated | Needham | Buy |
| Apr-04-18 | Upgrade | Needham | Hold → Buy |
View All
Globus Medical Inc Stock (GMED) Latest News
Insider plans sale of 3,594 common shares under Rule 144 | GMED SEC FilingForm 144 - Stock Titan
GMED (GMED) holder files to sell 2,000 shares after RSU vesting - Stock Titan
Is Globus Medical Inc. stock dividend yield sustainableQuarterly Trade Report & Expert Curated Trade Ideas - ulpravda.ru
Globus Medical jumps 9% after upbeat revenue and earnings outlook - Yahoo Finance
Globus Medical (GMED) Price Target Raised to $115.00 by Piper Sa - GuruFocus
Will Globus Medical Inc. stock benefit from automationWeekly Market Outlook & Stepwise Entry/Exit Trade Alerts - ulpravda.ru
Globus Medical stock hits all-time high at 99.5 USD By Investing.com - Investing.com Canada
Globus Medical climbs on better-than-expected Q4, FY outlook - TradingView — Track All Markets
US-based Globus Medical anticipates 25.2% sales increase in Q4 2025 - Medical Buyer
Citizens reiterates Market Perform rating on Globus Medical stock By Investing.com - Investing.com Canada
Globus Medical (GMED) Surges on Strong Sales Projections - GuruFocus
Jon Najarian: Globus Medical shares surge 9 percent on strong Q4 sales projection - Traders Union
Jefferies raises Globus Medical stock price target to $115 on strong Q4 - Investing.com Canada
Why Globus Medical Stock Is Flying Higher in After-Hours Trading - The Globe and Mail
Globus Medical Surges On Preliminary Q4 And FY25 Sales Results; Issues FY26 Guidance - Nasdaq
Globus Medical Stock Pre-Market (+9.3%): Strong Prelim Q4 Sales & Upbeat 2026 Guidance - Trefis
Globus Medical reports 25.2% revenue growth in Q4 2025 By Investing.com - Investing.com Nigeria
Globus Medical (GMED) Projects Strong Revenue Growth for 2025 - GuruFocus
GMED Sees Strong Q4 Results, Eyes Growth in 2026 - GuruFocus
Globus Medical Q4 Preliminary Sales Rise 25% From Year Earlier; Shares Jump After Hours - MarketScreener
GMED Stock Sees Significant Annual Growth - GuruFocus
GMED Raises Revenue Forecast for FY26 - GuruFocus
Globus Medical reports 25.2% revenue growth in Q4 2025 - Investing.com India
Globus Medical's preliminary Q4 sales beat estimates - TradingView — Track All Markets
Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results - The Manila Times
Globus Medical (GMED) shares preliminary 2025 sales results and 2026 guidance - Stock Titan
Globus posts record 2025 sales, sets 2026 revenue guidance up to $3.22B - Stock Titan
Stifel raises Globus Medical stock price target to $90 on strong outlook - Investing.com Canada
Will Globus Medical Inc. stock attract ESG investors2026 world cup usa national team qualification top scorers counter attacking winner prediction tactical review - ulpravda.ru
Globus Medical (GMED) director gifts 6,100 Class A shares, updates holdings - Stock Titan
Globus Medical Inc Shs A Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh A - TradingView — Track All Markets
Does Globus Medical (NYSE:GMED) Deserve A Spot On Your Watchlist? - Yahoo Finance
Allspring Global Investments Holdings LLC Acquires 312,149 Shares of Globus Medical, Inc. $GMED - MarketBeat
Globus Medical (NYSE:GMED) Rating Increased to Strong-Buy at Wall Street Zen - MarketBeat
Globus Medical Inc: The Spine Stock Wall Street Slept On (Until Now) - AD HOC NEWS
Globus Medical (GMED) Lags Q1 Earnings and Revenue Estimates - sharewise.com
The Truth About Globus Medical Inc: Why Wall Street Suddenly Can’t Ignore It - AD HOC NEWS
Fort Washington Investment Advisors Inc. OH Raises Holdings in Globus Medical, Inc. $GMED - MarketBeat
Globus Medical (NYSE:GMED) Listed in NYSE Composite Healthcare Group - Kalkine Media
Should I hold or sell Globus Medical Inc. stock in 2025Debt-to-Equity Ratio Analysis & Free High Yield Investment Strategies - bollywoodhelpline.com
Globus Medical, Inc. $GMED is Paradice Investment Management LLC's Largest Position - MarketBeat
BTIG reiterates Neutral rating on Globus Medical stock after strong Q3 - Investing.com Canada
Audubon’s Globus Medical Makes Game-Changing Acquisition - MSN
Boston Trust Walden Corp Takes $67.89 Million Position in Globus Medical, Inc. $GMED - MarketBeat
Globus Medical, Inc. (NYSE:GMED) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Globus Medical, Inc. Class A Common Stock (NYSE:GMED) Stock Quote - FinancialContent
Swedbank AB Increases Position in Globus Medical, Inc. $GMED - MarketBeat
Globus Medical (GMED): Assessing Valuation After a 60% Three-Month Share Price Surge - Sahm
Globus Medical (STU:GM0N) EV-to-OCF : 15.30 (As of Dec. 24, 2025) - GuruFocus
Globus Medical Earnings Notes - Trefis
Here's Why Globus Medical (GMED) is a Strong Growth Stock - sharewise.com
Globus Medical Inc Stock (GMED) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.10%
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):